{"id":"oral-ciprofloxacin-plus-inhaled-colistin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Tendinopathy (ciprofloxacin)"},{"rate":null,"effect":"Nephrotoxicity (colistin)"},{"rate":null,"effect":"Neurotoxicity (colistin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Inhaled colistin is a polymyxin antibiotic that binds to and disrupts the outer membrane of gram-negative bacteria. The combination targets multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa in cystic fibrosis, through complementary mechanisms to enhance bacterial eradication.","oneSentence":"Ciprofloxacin and colistin are combined to provide synergistic bacterial killing through different mechanisms: ciprofloxacin inhibits DNA gyrase while colistin disrupts bacterial cell membranes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:38:56.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection"}]},"trialDetails":[{"nctId":"NCT00411736","phase":"PHASE4","title":"Scandinavian Cystic Fibrosis Azithromycin Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2008-05","conditions":"Cystic Fibrosis","enrollment":45},{"nctId":"NCT01400750","phase":"PHASE4","title":"Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2001-08","conditions":"Cystic Fibrosis","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ciproxin ® - ciprofloxacin","Colistineb ®"],"phase":"marketed","status":"active","brandName":"oral ciprofloxacin plus inhaled colistin","genericName":"oral ciprofloxacin plus inhaled colistin","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin and colistin are combined to provide synergistic bacterial killing through different mechanisms: ciprofloxacin inhibits DNA gyrase while colistin disrupts bacterial cell membranes. Used for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}